uploads///Invanz and Cancidas

How Did Merck’s Invanz and Cancidas Perform in 2017?

By

Mar. 16 2018, Updated 6:30 a.m. ET

Invanz revenue trends

In 4Q17, Merck’s (MRK) Invanz generated revenues of $157 million, which represents a ~3% rise on a YoY (year-over-year) basis and a 1% decline on a QoQ (quarter-over-quarter). In 4Q17, in the US and in international markets, Invanz generated revenues of $93 million and $64 million, respectively, compared with $90 million and $63 million in 4Q16, which represents a ~4% rise and a ~2% rise, respectively, YoY.

Article continues below advertisement

In 2017, Invanz reported revenues of $602 million, compared with $561 million in 2016, which is ~7% higher YoY. In 2017, in the US and in international markets, Invanz reported revenues of $361 million and $241 million, respectively, compared with $329 million and $233 million in 2016, which is ~10% and ~4% higher YoY.

Higher sales of Invanz in the US attributed to the revenue growth of this drug in 2017. The international sales of Invanz had a 2% unfavorable effect from foreign exchanges.

Cancidas revenue trends

In 4Q17, Cancidas reported revenues of $95 million, which is ~38% higher on a YoY basis and 1% higher on a QoQ basis. In fiscal 2017, Cancidas reported revenues of $422 million, compared with $558 million in 2016, which was ~24% lower on a YoY basis.

In 2017, in the US and in international markets, Cancidas reported revenues of $20 million and $402 million, respectively, compared with $25 million and $533 million in 2016, which was ~16% lower and ~25% lower, respectively, YoY.

Cancidas is used for the treatment of fungal infections. Cancidas is primarily sold outside of the US. Cancidas witnessed a decline in revenues globally, primarily due to the increased competition from the generic versions of the drug in some European markets. Due to competition from the generic versions of the drug, Merck anticipates that Cancidas sales could continue to decline over 2018.

In the marketplace, Cancidas competes with Pfizer’s (PFE) Anidulafungin and Astellas Pharma’s (ALPMY) Micafungin.

Advertisement

More From Market Realist